Sanjaya Kumar Satapathy1, Chandra Sekhar Lingisetty1, Susan Williams2. 1. Department of Internal Medicine, New York Medical College/Metropolitan Hospital Center, New York, 10029, USA. 2. Department of Gastroenterology, New York Medical College/Metropolitan Hospital Center, 1901 First Avenue, New York, 10029, USA. susan.williams@nychhc.org.
Abstract
BACKGROUND: The role of hepatitis C virus infection (HCV) in the etiology and progression of chronic kidney disease (CKD) is controversial. AIM: To measure the prevalence of CKD and evaluate its course in patients with chronic HCV infection. METHODS: A retrospective analysis was done after excluding patients with nephrolithiasis, structural kidney disease, and those with missing clinical information on 552 anti-HCV-positive patients and 313 patients without known HCV infection matched for age, race, and gender. CKD was defined as estimated glomerular filtration rate value of <60 mL/min/1.73 m(2) and/or persistence of proteinuria (>3 months) on urine analysis by dipstick. Viral load obtained during the initial evaluation was defined as "baseline viral load". RESULTS: The prevalence of CKD in the anti-HCV-positive group was significantly higher compared to control group [53 (9.6%) vs. 16 (5.1%), P = 0.02]. On multivariate regression analysis, higher age, hypertension, HCV PCR > 7 × 10(5) cps/mL, and diabetes mellitus were significant independent positive predictors, whereas history of interferon treatment was significant independent negative predictor for CKD. Male gender, human immunodeficiency virus status, body weight, intravenous drug use, and HCV genotype were not predictors of CKD. Analysis of renal survival through Kaplan-Meyer curves revealed significantly shorter time to develop CKD (74 vs. 84 months, P < 0.001; log rank) and end-stage renal disease (79.9 vs. 86.5 months, P = 0.005; log rank) in the HCV group compared to the control group. CONCLUSION: Chronic HCV infection was associated with a significantly higher prevalence of CKD compared with controls, as well as significantly shorter renal survival. A higher baseline viral load is an independent predictor of CKD.
BACKGROUND: The role of hepatitis C virus infection (HCV) in the etiology and progression of chronic kidney disease (CKD) is controversial. AIM: To measure the prevalence of CKD and evaluate its course in patients with chronic HCV infection. METHODS: A retrospective analysis was done after excluding patients with nephrolithiasis, structural kidney disease, and those with missing clinical information on 552 anti-HCV-positive patients and 313 patients without known HCV infection matched for age, race, and gender. CKD was defined as estimated glomerular filtration rate value of <60 mL/min/1.73 m(2) and/or persistence of proteinuria (>3 months) on urine analysis by dipstick. Viral load obtained during the initial evaluation was defined as "baseline viral load". RESULTS: The prevalence of CKD in the anti-HCV-positive group was significantly higher compared to control group [53 (9.6%) vs. 16 (5.1%), P = 0.02]. On multivariate regression analysis, higher age, hypertension, HCV PCR > 7 × 10(5) cps/mL, and diabetes mellitus were significant independent positive predictors, whereas history of interferon treatment was significant independent negative predictor for CKD. Male gender, human immunodeficiency virus status, body weight, intravenous drug use, and HCV genotype were not predictors of CKD. Analysis of renal survival through Kaplan-Meyer curves revealed significantly shorter time to develop CKD (74 vs. 84 months, P < 0.001; log rank) and end-stage renal disease (79.9 vs. 86.5 months, P = 0.005; log rank) in the HCV group compared to the control group. CONCLUSION:Chronic HCV infection was associated with a significantly higher prevalence of CKD compared with controls, as well as significantly shorter renal survival. A higher baseline viral load is an independent predictor of CKD.
Authors: Alaa A Sabry; Mohamed A Sobh; William L Irving; Anna Grabowska; Bart E Wagner; Samantha Fox; Gura Kudesia; A Meguid El Nahas Journal: Nephrol Dial Transplant Date: 2002-02 Impact factor: 5.992
Authors: Sharon M Moe; A J Pampalone; Susan Ofner; Marc Rosenman; Evgenia Teal; Siu L Hui Journal: Am J Kidney Dis Date: 2008-04-28 Impact factor: 8.860
Authors: Shruti H Mehta; Frederick L Brancati; Steffanie A Strathdee; James S Pankow; Dale Netski; Josef Coresh; Moyses Szklo; David L Thomas Journal: Hepatology Date: 2003-07 Impact factor: 17.425
Authors: Trevor A Crowell; Kelly A Gebo; Ashwin Balagopal; John A Fleishman; Allison L Agwu; Stephen A Berry Journal: J Acquir Immune Defic Syndr Date: 2014-04-01 Impact factor: 3.731
Authors: Miklos Z Molnar; Hazem M Alhourani; Barry M Wall; Jun L Lu; Elani Streja; Kamyar Kalantar-Zadeh; Csaba P Kovesdy Journal: Hepatology Date: 2015-03-20 Impact factor: 17.425
Authors: Trevor A Crowell; Stephen A Berry; John A Fleishman; Richard W LaRue; Philip T Korthuis; Ank E Nijhawan; Richard D Moore; Kelly A Gebo Journal: J Acquir Immune Defic Syndr Date: 2015-04-01 Impact factor: 3.731
Authors: Angela Sciacqua; Maria Perticone; Eliezer J Tassone; Antonio Cimellaro; Benedetto Caroleo; Sofia Miceli; Michele Andreucci; Anna Licata; Giorgio Sesti; Francesco Perticone Journal: Intern Emerg Med Date: 2015-11-23 Impact factor: 3.397
Authors: Matthew P Kosloski; Weihan Zhao; Thomas C Marbury; Richard A Preston; Michael G Collins; David Pugatch; Federico Mensa; Jens Kort; Wei Liu Journal: Antimicrob Agents Chemother Date: 2018-02-23 Impact factor: 5.191
Authors: Jaeyoun Cheong; Joseph A Galanko; Sumant Arora; Joaquin Cabezas; Nambi J Ndugga; Michael R Lucey; Paul H Hayashi; Alfred Sidney Barritt; Ramon Bataller Journal: Liver Int Date: 2016-07-04 Impact factor: 5.828